suggest using anti-PD-1/PD-L1 in combination with other checkpoint inhibitors or chemotherapy, targeted therapy, radiotherapy, or with novel immunotherapies to increase the efficacy of immunotherapies in breast cancers. The gene discussed is PDCD1; the disease is breast carcinoma.